{"title":"Dronedarone: a new option in atrial fibrillation","authors":"Professor A. John Camm MD, Irina Savelieva MD","doi":"10.1002/fps.45","DOIUrl":null,"url":null,"abstract":"<p>Many antiarrhythmic agents exploiting new mechanisms of action (as well as modified analogues of traditional antiarrhythmic drugs, with different combinations of ion channel- and receptor-blocking effects and less complicated metabolic profiles) are currently being investigated. Dronedarone is an amiodarone derivative that is devoid of iodine atoms and is believed to have a better safety profile than amiodarone. It is the only antiarrhythmic drug for the treatment of atrial fibrillation (AF) that has been shown to improve survival in high-risk patients. This review provides a contemporary insight into the clinical development of dronedarone, its efficacy and safety in preventing recurrent AF, and its potential additional advantage of improving outcome in patients with AF. Copyright © 2009 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 1","pages":"24-32"},"PeriodicalIF":0.0000,"publicationDate":"2009-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.45","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.45","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Many antiarrhythmic agents exploiting new mechanisms of action (as well as modified analogues of traditional antiarrhythmic drugs, with different combinations of ion channel- and receptor-blocking effects and less complicated metabolic profiles) are currently being investigated. Dronedarone is an amiodarone derivative that is devoid of iodine atoms and is believed to have a better safety profile than amiodarone. It is the only antiarrhythmic drug for the treatment of atrial fibrillation (AF) that has been shown to improve survival in high-risk patients. This review provides a contemporary insight into the clinical development of dronedarone, its efficacy and safety in preventing recurrent AF, and its potential additional advantage of improving outcome in patients with AF. Copyright © 2009 John Wiley & Sons, Ltd.
Dronedarone:房颤治疗的新选择
目前正在研究许多利用新的作用机制的抗心律失常药物(以及传统抗心律失常药物的改良类似物，具有离子通道和受体阻断作用的不同组合以及不太复杂的代谢谱)。克隆酮是一种胺碘酮衍生物，不含碘原子，被认为比胺碘酮具有更好的安全性。它是治疗心房颤动(AF)的唯一抗心律失常药物，已被证明可提高高危患者的生存率。本综述提供了关于drone - edarone临床发展的当代见解，它在预防复发性房颤中的有效性和安全性，以及它在改善房颤患者预后方面的潜在额外优势。版权©2009 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
